


# FUNDAMENTALS OF PHARMACOLOGY

SHANE BULLOCK AND ELIZABETH MANIAS **7th EDITION**

# FUNDAMENTALS OF PHARMACOLOGY







# FUNDAMENTALS OF PHARMACOLOGY

SHANE BULLOCK AND ELIZABETH MANIAS **7th EDITION**

Copyright © Pearson Australia (a division of Pearson Australia Group Pty Ltd) 2014  
Pearson Australia  
Unit 4, Level 3  
14 Aquatic Drive  
Frenchs Forest NSW 2086

www.pearson.com.au

The *Copyright Act 1968* of Australia allows a maximum of one chapter or 10% of this book, whichever is the greater, to be copied by any educational institution for its educational purposes provided that that educational institution (or the body that administers it) has given a remuneration notice to Copyright Agency Limited (CAL) under the Act. For details of the CAL licence for educational institutions contact:  
Copyright Agency Limited, telephone: (02) 9394 7600, email: info@copyright.com.au

All rights reserved. Except under the conditions described in the *Copyright Act 1968* of Australia and subsequent amendments, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the copyright owner.

Senior Acquisitions Editor: Mandy Shepherd  
Senior Project Editor: Rebecca Pomponio  
Development Editor: Katie Pittard  
Editorial Coordinator: Sophie Attwood  
Production Controller: Julie McArthur  
Copy Editor: Biotext Pty Ltd  
Proofreader: Jane Tyrrell  
Senior Copyright and Pictures Editor: Emma Gaulton  
Indexer: Garry Cousins  
Cover and internal design by Natalie Bowra  
Cover illustration © MEDI-MATION/Science Photo Library  
Typeset by Midland Typesetters, Australia

Printed in China

1 2 3 4 5 18 17 16 15 14

National Library of Australia  
Cataloguing-in-Publication Data

Author: Bullock, Shane, author.  
Title: Fundamentals of pharmacology / Shane Bullock, Elizabeth Manias.  
Edition: 7th edition.  
ISBN: 9781442563100 (paperback).  
ISBN: 9781442564411 (Vital Source)  
Notes: Includes index.  
Subjects: Pharmacology—Study and teaching (Higher). Drugs—Study and teaching (Higher)  
Other Authors/Contributors: Manias, Elizabeth, author.  
Dewey Number: 615.1900711

Every effort has been made to trace and acknowledge copyright. However, should any infringement have occurred, the publishers tender their apologies and invite copyright owners to contact them. Due to copyright restrictions, we may have been unable to include material from the print edition of the book in this digital edition, although every effort has been made to minimise instances of missing content.

# CONTENTS



	Preface	viii
	Acknowledgments	x
	Features	xi
	Teaching and learning package	xv
	Figures and tables	xvi
<b>SECTION I</b>	<b>PHARMACOLOGY WITHIN THE SOCIAL CONTEXT</b>	<b>1</b>
	1 A historical perspective	2
	2 Sociocultural aspects	8
<b>SECTION II</b>	<b>PHARMACOLOGY WITHIN THE PROFESSIONAL CONTEXT</b>	<b>19</b>
	3 Health professionals and the law	21
	4 Ethical issues	30
	5 The roles and responsibilities of health professionals in medicine adherence, education and advocacy	39
	6 The roles and responsibilities of health professionals in medicine management	44
<b>SECTION III</b>	<b>MEDICINE ADMINISTRATION AND PROFESSIONAL RESPONSIBILITIES</b>	<b>55</b>
	7 Medicine formulations, storage and routes of administration	56
	8 The clinical decision-making process	76
	9 Medicine administration strategies and documentation	82
	10 Medication errors	92
	11 Management of common adverse drug reactions	96
	12 Risk communication: balancing the benefits and risks of drug treatment	113
<b>SECTION IV</b>	<b>GENERAL ASPECTS OF PHARMACOLOGY</b>	<b>125</b>
	13 Drug nomenclature	127
	14 Pharmacokinetics: absorption and distribution	133
	15 Pharmacokinetics: metabolism and excretion	142
	16 Drug interactions	152
	17 Pharmacodynamics	159
	18 Drug development, evaluation and safety	171
	19 Pharmacogenetics	182
	20 Pharmacokinetic factors that modify drug action	190
	21 Paediatric and geriatric pharmacology	195
<b>SECTION V</b>	<b>TOXICOLOGY</b>	<b>209</b>
	22 Poisoning and envenomation	210
	23 The management of acute clinical overdose	218
	24 Contemporary drugs of abuse	227
	25 Drug abuse in sport	239

SECTION VI	<b>AUTONOMIC PHARMACOLOGY</b>	<b>249</b>
	26 General aspects of neuropharmacology	250
	27 Adrenergic pharmacology	258
	28 Cholinergic pharmacology	286
SECTION VII	<b>CHEMICAL MEDIATORS</b>	<b>313</b>
	29 An introduction to chemical mediators	314
	30 Histamine and antihistamines	318
	31 Prostaglandins and serotonin	329
	32 Nitric oxide and the endothelins	337
SECTION VIII	<b>THE MODULATION OF BEHAVIOUR, COGNITION AND MOTOR ACTIVITY</b>	<b>345</b>
	33 General concepts of psychopharmacology	347
	34 Antipsychotic agents	352
	35 Anxiolytics and hypnotics	367
	36 Antidepressants and mood stabilisers	380
	37 Medicines used in neurodegenerative disorders	399
	38 Antiseizure agents and muscle relaxants	418
	39 Central nervous system stimulants	437
SECTION IX	<b>MEDICINES USED TO RELIEVE PAIN AND PRODUCE ANAESTHESIA</b>	<b>447</b>
	40 Narcotic analgesics	448
	41 Non-steroidal anti-inflammatory, antipyretic and analgesic agents	466
	42 Medicines used to treat migraine	488
	43 General anaesthesia	498
	44 Local anaesthesia	508
SECTION X	<b>THE MODULATION OF OXYGENATION AND PERFUSION</b>	<b>521</b>
	45 Medicines used to lower blood lipids	522
	46 Antihypertensive agents	534
	47 Medicines used to promote tissue perfusion	556
	48 Antithrombotic, fibrinolytic and haemostatic agents	572
	49 Diuretics and other renal medicines	594
	50 Medicines used to treat heart failure	606
	51 Medicines used to treat cardiac dysrhythmia	626
	52 Fluid and potassium imbalances	636
	53 Antianaemic agents	651
	54 Medicines used to maintain gas exchange	659
	55 Medicines for upper respiratory tract conditions	681
SECTION XI	<b>THE MODULATION OF GASTROINTESTINAL FUNCTION</b>	<b>697</b>
	56 Upper gastrointestinal tract drugs	698
	57 Lower gastrointestinal tract drugs	713
	58 Antiemetic agents	734



SECTION XII	<b>THE MODULATION OF BODY GROWTH, DEVELOPMENT AND METABOLISM</b>	<b>747</b>
	59 Medicines and the pituitary gland	749
	60 Medicines and the thyroid	762
	61 Medicines and the pancreas	770
	62 Medicines and the adrenal cortex	791
	63 Medicines and the gonads	801
	64 Medicines and bone metabolism	822
	65 Hyperuricaemia and gout	833
	66 Obesity and its treatment	842
SECTION XIII	<b>NUTRITIONAL AND NATURAL THERAPIES</b>	<b>855</b>
	67 Vitamins, minerals and amino acids	856
	68 Enteral and parenteral nutrition	876
	69 Herbal medicines	886
SECTION XIV	<b>THE MODULATION OF CELLULAR GROWTH AND PROLIFERATION</b>	<b>907</b>
	70 Introduction to chemotherapy	909
	71 Sulfonamides and trimethoprim	917
	72 Antibacterial agents	923
	73 Antituberculotics and antileprotic agents	947
	74 Antiseptics and disinfectants	960
	75 Antiparasitic agents	969
	76 Antimalarial agents	981
	77 Antiviral agents	991
	78 Antifungal agents	1012
	79 Immunomodulating agents	1025
	80 Cytotoxic chemotherapeutic agents	1050
	81 Gene therapies	1080
SECTION XV	<b>MEDICINES USED TOPICALLY</b>	<b>1089</b>
	82 Medicines used in diseases of the skin	1090
	83 Medicines and the eye	1111
APPENDIX	<b>A Common prescription terminology</b>	<b>1135</b>
	<b>B Common American generic drug names</b>	<b>1136</b>
	<b>C SI units</b>	<b>1137</b>
	<b>D Medicine calculations</b>	<b>1140</b>
	<b>E Common symbols used in medication charts</b>	<b>1145</b>
	<b>F Common word mix-ups</b>	<b>1146</b>
	<b>G Drug–herbal interactions</b>	<b>1148</b>
	<b>H Orphan drugs</b>	<b>1150</b>
	Glossary	1153
	Index	1165



# PREFACE

*Fundamentals of Pharmacology* is primarily a text for undergraduate and postgraduate students in the health science disciplines, particularly those in nursing. Students of other health disciplines whose roles involve pharmacological therapy (such as pharmacy, podiatry, optometry, paramedic and physiotherapy), as well as those studying basic science, should find much of the material relevant to their studies. Qualified health professionals and pharmaceutical company sales representatives will also find the information useful in their daily roles. Unashamedly, we have written a pharmacology textbook for students of the health professions that does not compromise the scientific basis of the discipline. Many pharmacology texts previously published have been strong on clinical considerations, yet relatively weak in the science of pharmacology.

## **Our approach**

Philosophically, our goal is to empower health professionals through an understanding of the fundamental scientific principles of pharmacology. We believe that, to promote understanding, the effects of drugs on physiological and pathophysiological processes have to be clearly explained. We have included a small amount of chemistry and biochemistry where appropriate in order to facilitate this understanding. With a greater appreciation of the action of drugs and their target tissues, the reader should be able to deduce what adverse effects to expect, as well as the precautions and contraindications to consider.

Furthermore, where possible we have tended to describe the important characteristics of medicine groupings rather than focusing on individual agents, and have used prototypes and common generics as examples. The rationale for this approach is that new medicines are regularly entering the market while older agents are removed. The average practitioner cannot possibly keep up with all these changes. However, if a student knows which grouping a new agent belongs to, the principal characteristics of the medicine can be easily deduced.

This book is primarily designed to establish the foundations in pharmacology. We encourage students to refer to the electronic and hard copy references commonly found in the clinical setting and in hospital wards, such as the *Australian Medicines Handbook*, *MIMS* or *Therapeutic Guidelines*, for more detailed information regarding individual therapeutic agents (e.g. dosage, special precautions and toxicological information).

We hope that you will find this textbook a valuable companion in your pursuit of a fundamental understanding in a most fascinating area of clinical knowledge—pharmacology.

## **Changes in the seventh edition**

This edition reflects the availability of medicines in Australia and New Zealand at the time of publication. Consistent with information currently available to us, we have updated new medicines that have entered the marketplace, as well as those that have been removed since the last edition.

We use the word “medicine” rather than “drug” or “medication” where appropriate. This change was implemented in recognition of the increasing use of the word “medicine” as evidenced by a number of industry websites such as:

- the National Prescribing Service ([www.nps.org.au](http://www.nps.org.au));
- Australian Prescriber ([www.australianprescriber.com](http://www.australianprescriber.com)); and
- the Therapeutic Goods Administration ([www.tga.gov.au/industry/pm.htm](http://www.tga.gov.au/industry/pm.htm)).

Where appropriate, the therapeutic approaches associated with the management of important clinical conditions, such as cardiovascular disease, diabetes mellitus and psychiatric illness have been brought up to date with current clinical guidelines.

### FULL COLOUR FIGURES AND TABLES

This edition is printed in full colour for the first time. Chapter figures are more dynamic, providing the representations of structures and processes with greater depth and vibrancy. Receptors are rendered more often in figures as G-protein-coupled or ion channels rather than basic geometric shapes.

A number of new figures and tables have been included to assist students in visualising difficult pharmacological concepts, the sites of actions of drugs and the range of drug effects expected in a person when particular drug groups are administered.

### END-OF-CHAPTER AND END-OF-SECTION FEATURES

The book contains over 800 end-of-chapter questions to assist in the consolidation of learning—all of these have been reviewed.

New and revised integrated case studies appear at the end of sections to assist with making links between theory and practice.

# ACKNOWLEDGMENTS

We would like to thank a number of people who have contributed to the development of this textbook, and this edition in particular. Elizabeth wishes to thank her family for their patience and support, and for giving her an appreciation of things beyond the world of medicines. She would also like to thank her colleagues and students, who have provided her with helpful comments about the textbook and made suggestions for improvement.

For Shane the writing of this edition was fuelled by the primary producers situated around his homebase in the Gippsland region of Victoria—yummy cheese, chutney, jam and wine. With respect to the latter indulgence, students are advised to do as I say (see Chapter 24) rather than as I do. He is grateful to the backyard chooks who proved to be a more receptive and attentive audience than other family members when workshopping new ideas for the book.

We would like to thank the team at Pearson Australia for the preparation of this edition. Our thanks to Mandy Sheppard for her support, encouragement and good humour. We are also grateful for access to the expertise of Katie Pittard, Emma Gaulton and Rebecca Pomponio. It is always a pleasure working with you. We thank our copy editor, Anneliese Gillard, and proofreader, Jane Tyrrell, for their valuable advice on contemporary word usage and for picking up on our writing idiosyncrasies.

Thanks also to the proposal reviewers:

- Peter Athanasos, Flinders University
- Dr Hemant Mehta, Australian Catholic University
- Rebekkah Middleton, University of Wollongong
- Dr Srinivas Nammi, University of Western Sydney
- Dr Nicole Reinke, James Cook University
- Dr Ross Richards, Charles Sturt University
- Dr Scott Smid, The University of Adelaide
- Dr Jenny Wilkinson, Charles Sturt University

Shane Bullock and Elizabeth Manias

*July 2013*

# FEATURES

**CHAPTER 1**

## A HISTORICAL PERSPECTIVE

**LEARNING OBJECTIVES**  
After completing this chapter, you should be able to:

- 1 Define the term pharmacology.
- 2 Identify the roles of medicines in human society.
- 3 Identify the three ages of pharmacology.
- 4 Briefly describe the major characteristics of each of the three ages and their implications for society.

**KEY TERMS**  
*Biotechnology*  
*Genetic engineering*  
*Natural products*  
*Pharmacology*  
*Recombinant DNA technology*

Pharmacology is a branch of medical science that deals with the properties and characteristics of chemical agents used for medicinal or other purposes. The actions and effects of these chemical agents on physiological systems are of particular interest. The physiological systems in which these effects are observed may be organs or tissues isolated from the body and artificially maintained—in vitro situations—or within living whole organisms—in vivo situations. In an etymological sense, the word 'pharmacology' is derived from two Greek words: *pharmakos*, which means medicine or drug, and *logos*, which means study.

Learning Objectives make clear what students will learn in each chapter.

Key Terms introduce students to new terminology and are helpful when revising for exams.

**CHAPTER 67**

## VITAMINS, MINERALS AND AMINO ACIDS

**LEARNING OBJECTIVES**  
After completing this chapter, you should be able to:

- 1 List the functions, usage and dangers of vitamin A.
- 2 Name the functions and uses of members of the vitamin B group.
- 3 Name the functions and use of ascorbic acid.
- 4 Describe the functions of vitamins E and K.
- 5 Describe the role of trace elements in human metabolism and disease.
- 6 Outline the role of fluoride in the prevention of tooth decay and osteoporosis.
- 7 Describe the role of zinc salts in therapeutics.
- 8 Describe the difference between the D- and L-forms of amino acids.
- 9 Explain the significance of amino acids in disorders of metabolism.
- 10 Describe the treatment of metabolic disorders using the various amino-acid-free preparations.
- 11 List the amino acids that can be used in therapeutics.

**KEY TERMS**  
*Amino acids*  
*Disorders of metabolism*  
*Elemental ions*  
*Fat-soluble vitamins*  
*Hepatic encephalopathy*  
*Macrominerals*  
*Maple-syrup-urine disease*  
*Microminerals*  
*Mineral supplementation*  
*Over-the-counter (OTC) medicines*  
*Phenylketonuria*  
*Vitamin supplementation*  
*Water-soluble vitamins*

This chapter deals with vitamins, minerals and amino acids. All these substances work in complex ways to enable metabolic processes to occur efficiently in the body.



- 2 What is a chelating agent?
- 3 Name the agent(s) used in the treatment of poisoning by each of the following substances:
  - a cyanide
  - b lead
  - c mercury
  - d pesticides
- 4 Define the term envenomation.
- 5 State the three aims of emergency care when someone is bitten or stung by a venomous animal.
- 6 Your neighbour visits you in an extremely distressed state. Joey, her three-year-old son, has just swallowed an unknown quantity of paracetamol tablets. What would you advise her to do? Why?
- 7 Mario Malodoro, a 60-year-old farmer, is brought into the emergency department with organophosphate poisoning. How would this form of poisoning be treated?
- 8 While clearing rubbish in his backyard, 28-year-old Jeffrey Abeicot is bitten on the hand by a redback spider. His partner bandages his hand and arm firmly. She then drives him to your clinic, which is only five minutes down the road. Comment on the suitability of this treatment. Describe the management of this type of envenomation.

## 22 MEDICINE SUMMARY TABLE

FAMILY NAME	GENERIC NAME	TRADE NAME(S)
Emetic	ipecaacuana	
Adsorbent	activated charcoal + sorbitol	Carbosorb X Carbosorb XS
Iso-osmotic laxatives	electrolytes + polyethylene glycol + ascorbic acid	ColonLYTEL Glycoprep Glycoprep-C Klean Prep/Movicol Movicol-Half Moviprep
Methanol intoxication	ethanol + glucose	
Cyanide antidote	amyl nitrite dicobalt edotrate sodium nitrite sodium thiosulfate	
Organophosphate antidotes	atropine sulfate pralidoxime iodide	PAM injection


✓ Australia only  
 ✦ New Zealand only

**Medicine Summary Tables** provide a handy list of family names, generic names and trade names for specific medicines.

**Icons** indicate medicines that are only available in Australia or New Zealand. Special considerations are listed where necessary.

**Figures** illustrate and clarify complex processes, aiding student comprehension.

Figure 27.1 Adrenergic nerve action



## CLINICAL MANAGEMENT

## SYMPATHOMIMETICS

## Assessment

- Obtain baseline vital signs for the person. Report any abnormal findings. These include blood pressure and rate, and rhythm of pulse. Assess colour and temperature of the person's extremities (for drugs with  $\alpha_1$  effects). Conscious state is assessed to determine cerebral perfusion (this is an important consideration if the medicine is administered intravenously for the purpose of maintaining blood pressure). Determine rate, rhythm and depth of respiration. Assess for wheezing if the medicine is used for asthma. Listen to the heart with a stethoscope for dysrhythmias and palpitations (for drugs with  $\alpha_1$  or  $\beta_1$  effects). Compare the person's apical beat with the radial rate. A difference indicates irregularity in rhythm. Determine urinary output and assess for bladder distension (for drugs with  $\alpha_1$  effects).
- Assess whether the person has a history of the following:
  - glaucoma or prostatic hypertrophy (for drugs with  $\alpha_1$  effects);
  - cardiovascular, cerebrovascular or circulatory disease, hyperthyroidism (for drugs with  $\alpha_1$  or  $\beta_1$  effects);
  - diabetes mellitus (for drugs with  $\alpha_1$  or  $\beta_1$  effects). The sympathomimetic agent may intensify the condition, therefore, leading to elevated blood glucose levels from increased glycogen breakdown. The situation would require further clarification with the prescriber.
- Determine whether the person is taking monoamine oxidase inhibitors, phloretins or digoxin, as their effects can be either nullified or intensified by the administration of sympathomimetics.

## Planning

- The person's vital signs will remain within an acceptable range for the person.
- The person will experience minimal or no adverse effects from the sympathomimetic.

## Implementation

- Carefully and regularly monitor the person's vital signs, conscious state and urinary output.
- Sympathomimetics administered intravenously can produce profound effects on vital organs at small

dosages. Their haemodynamic effects should, therefore, be carefully monitored and recorded. Dosages are then titrated according to the person's response. A large central vein should be used for the administration of intravenous sympathomimetics to prevent peripheral necrosis. The use of intravenous sympathomimetics is restricted generally to clinical settings in which close monitoring of venous and arterial pressures, electrocardiogram and urinary output can be performed, such as intensive care or coronary care units.

- Report and record adverse effects of the sympathomimetic, including palpitations, tachycardia (pulse greater than 100 beats/min), tremors or increased glucose levels.
- Regularly monitor the person's urinary output (for drugs with  $\alpha_1$  effects).
- Prolonged use of a sympathomimetic may lead to a diminished clinical effect, which is caused by a regulatory decrease in receptor numbers.


## Medicine education

- Drugs with  $\beta_1$  effects are usually given by inhalation or nebuliser. Check the methods for inhalation and nebulisation (refer to Chapter 7, Tables 7.17 and 7.18, for a description of methods).
- Instruct the person on the method of administering cold or flu preparations by nasal spray and drops (refer to Chapter 7, Tables 7.7 and 7.8, for description of methods).
- Instruct the person that nasal sprays used in excess could lead to a rebound nasal congestion. Directions for dosage should be carefully followed.
- Excessive use of bronchodilator inhalers could lead to adverse effects, such as tachycardia and skeletal muscle tremor. If asthma symptoms appear to be getting worse, the doctor should be consulted.
- Instruct the person to read all labels of over-the-counter preparations. Many of these preparations contain sympathomimetics and should not be taken if the person has a history of cardiac disease, diabetes, hypertension or cardiac dysrhythmias.

## Evaluation

- Examine the person's response to the sympathomimetic for expected and adverse effects. Continue to monitor

**Clinical Management Tables** highlight clinical applications of theory and utilise the clinical decision-making framework in a step-by-step process for care of the person.



erectile dysfunction, but it must be used with **papaverine** or **alprostadil** to be effective. Selective  $\alpha_1$  antagonists are used for control of hypertension. All  $\alpha_1$  antagonists may cause a rapid fall in blood pressure after the first dose. The patient should be advised to take the first dose at bedtime to reduce the consequences of this effect. The dose is then titrated slowly at two-weekly intervals. This hypotensive effect is likely to be more severe in the older person and in the individual who takes diuretics. It is recommended, therefore, that diuretics be withheld for a few days before commencing an  $\alpha_1$  antagonist. Postural hypotension and dizziness may occur and the person is advised to get up gradually from a lying or sitting position. Advise individuals to sit down if they become dizzy.

**B ANTAGONIST ACTION**

**Mechanism of action**

**Acebutolol, carvedilol, nadolol, oxprenolol, pindolol, propranolol, sotalol and timolol** are non-selective  $\beta$  antagonists or blockers. **Atenolol, betaxolol, bisoprolol, esmolol, nebivolol** and **metoprolol** are relatively  $\beta_1$ -selective (cardioselective) blocking drugs. Cardioselective

$\beta$ -blockers were developed to reduce potentially life-threatening reactions, such as bronchospasm, resulting from  $\beta_1$  receptor blockade. Acebutolol, oxprenolol and pindolol are partial agonists, and will induce sympathomimetic effects when there is low sympathetic tone.

Uniquely, nebivolol produces a therapeutic mild vasodilating effect through an interaction with the nitric oxide synthesis pathway.

**Common adverse effects**

The effects of  $\beta$ -blockers are shown in Figures 27.15 and 27.16. Common adverse effects include dizziness, lethargy, insomnia and diarrhoea. Contraindications include known hypersensitivity, heart block, severe heart failure, cardiogenic shock and other severe circulatory disorders, bradycardia with a heart rate of less than 45–50 beats per minute, sick sinus syndrome, atrioventricular block, severe hypotension or uncontrolled heart failure. They should also not be used in people with a history of asthma or chronic obstructive pulmonary disease.

**Clinical considerations**

Applications for  $\beta_1$  antagonists are to be found in the control of cardiac disease, hypertension, migraine prophylaxis, situational anxiety and thyrotoxicosis. In a seemingly counter-intuitive way, metoprolol, bisoprolol and carvedilol have been used judiciously in the management of heart failure (for details see Chapter 50). There are no clinical applications for  $\beta_2$  antagonists.

Abrupt withdrawal of  $\beta$  antagonists may accentuate angina or produce rebound hypertension, myocardial infarction or ventricular dysrhythmias. It is, therefore, important that  $\beta$  antagonists be slowly reduced when treatment is to cease. Cardioselective  $\beta$  antagonists may be preferred in conditions such as peripheral vascular disease, Raynaud's syndrome or diabetes mellitus because of their decreased effect on altering glucose metabolism and causing peripheral vasoconstriction. In diabetes, non-selective  $\beta$  antagonists may mask important signs of hypoglycaemia, including tachycardia and tremor, therefore increasing the severity of the condition. However,  $\beta_1$ -selectivity diminishes with higher doses of the medicine.

**NON-SELECTIVE ADRENERGIC BLOCKING AGENTS**

**Mechanism of action**

**Celiprolol** and **labetalol** non-selectively block both  $\alpha_1$  and  $\beta$  adrenoceptors in the periphery.

**Human Models** visually illustrate the effects, both positive and negative, of pharmacological agents on the human body. Male and female human models are used to illustrate the effects of pharmacological agents.

**Case Studies with Accompanying Questions** immerse students in scenarios involving people taking medicines, family members and health professionals. Students are given the opportunity to apply knowledge, practise drug calculations and dosages, and convey their understanding of pharmacological principles and interactions in a variety of clinical settings.

**CHAPTER REVIEW**

- Advertising of medicines can affect the medicine management activities of health professionals.
- Advertising can influence the medicinal activities of consumers.
- Over-the-counter preparations are available to consumers without a prescription, and often without supervision of a health professional.
- The generic name of a medicine is the shortened, simplified version of the chemical name.
- The brand name is the trademark used by a pharmaceutical company to identify the preparation of a particular drug.
- Generic prescribing means that a pharmacist can supply any formulation of a particular medicine.
- Generic substitution means that a pharmacist can supply any formulation of the medicine without referring back to the prescriber.
- Polypharmacy, which is a major problem for older people, involves the excessive or inappropriate use of medicines.
- The traditional beliefs and values of a particular culture influence an individual's perceptions and expectations about drug therapy.

**FURTHER READING**

Banning M. 2007. *Medication Management in Care of Older People*. Blackwell Publishing, Oxford.

Carmody D & Mansfield PR. 2010. 'What do medical students think about pharmaceutical promotion?' *Australian Medical Student Journal*, 1(1), 54–7.

DeLorme DE & Huh J. 2009. 'Seniors' uncertainty management of direct-to-consumer prescription drug advertising usefulness'. *Health Communication*, 24, 494–503.

Hamilton HJ, Gallagher PF & O'Mahony D. 2009. 'Inappropriate prescribing and adverse drug events in older people'. *BMC Geriatrics*, 9, 5, 28.

Peiris DP, Patel AA, Cass A, Howard MP, Tchan ML, Brady JP, De Vries J, Rickards BA, Yamold DJ, Hayman NE & Brown AD. 2009. 'Cardiovascular disease risk management for Aboriginal and Torres Strait Islander peoples in primary health care settings: Findings from the Kanyini audit'. *Medical Journal of Australia*, 191, 304–9.

Sparling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Ohman N & Vitry AJ. 2010. 'Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review'. *Public Library of Science Medicine*, 19(7)(10), e1000352.

Wessell AM, Nietert PJ, Jenkins RG, Nemeth LS & Ornstein SM. 2008. 'Inappropriate medication use in the elderly'. *American Journal of Geriatric Pharmacotherapy*, 6, 21–7.

**WEB RESOURCES**

A Brief History of Pharmacology [pubs.acs.org/subscribe/journals/mdd/v04/i05/html/05time.htm](http://pubs.acs.org/subscribe/journals/mdd/v04/i05/html/05time.htm)

Australian Bureau of Statistics [www.abs.gov.au/AUSSTATS](http://www.abs.gov.au/AUSSTATS)

What is Pharmacology? [www.pharmacology.med.umn.edu/whatispharm.html](http://www.pharmacology.med.umn.edu/whatispharm.html)

Everybody (Health Consumer Information) [www.everybody.co.nz](http://www.everybody.co.nz)

Maori Health [www.health.govt.nz/our-work/populations/maori-health](http://www.health.govt.nz/our-work/populations/maori-health)

New Zealand Deserves Better. Direct to Consumer Advertising (DTCA) of Prescription Medicines in New Zealand: for Health or Profit? [journal/116-1180/556](http://journal.nzma.org.nz/journal/116-1180/556)

Office for Aboriginal and Torres Strait Islander Health [www.health.gov.au/oatish](http://www.health.gov.au/oatish)

**CASE STUDY 1**

Mrs JH is a 62-year-old woman who has had rheumatoid arthritis in her hands, hips and knees for about eight years. She is receiving weekly assistance from her local district nursing service because of impaired mobility. For the arthritis, she is taking the non-steroidal anti-inflammatory drug ibuprofen daily and receives intermittent hydrocortisone therapy when the condition worsens.

You are caring for Mrs JH. She tells you that her eyes have 'not been the best of late' and she is finding it hard to see things out of the corners of her eyes. She is referred to her family doctor. He, in turn, refers her to the local eye clinic where a diagnosis of open-angle glaucoma is made. Mrs JH is prescribed eye drops containing a miotic agent. This medicine causes pupil constriction and facilitates the drainage of aqueous humour through the canal of Schlemm.

**Questions**

- a) Applying your knowledge of adrenergic and cholinergic pharmacology, which groups of drugs are well suited as miotics?

b) What receptor types are they acting on and how are they affecting the function of these receptors?
- a) State three common side-effects associated with each of these drug groups.

b) Would you expect to observe systemic side-effects associated with this therapy? Why?
- Referring to Chapter 19, explain why Mrs JH may be predisposed to glaucoma.

**CASE STUDY 2**

Mr FT is a 22-year-old man who has been admitted to your hospital emergency department. He has been working as a labourer at a nearby market garden that specialises in growing flowers. He was spraying the crops with the organophosphate insecticide malathion when he collapsed. He was not wearing the appropriate protective clothing. You observe that he is conscious and complains of gastrointestinal cramps and nausea. He vomited a couple of times in the ambulance as he was transported to hospital. You note the following manifestations: profuse sweating, drooling, lacrimation, bradycardia, agitation, muscle twitching and constricted pupils.

Supportive treatment is implemented, which involves respiratory support and the administration of anticholinergics. His progress is carefully monitored during this critical period. His recovery is without complications. He is discharged from hospital several days later.

**Questions**

- Underlying Mr FT's condition is a change in the level of activity of a division of the autonomic nervous system. Which division is affected and what is the nature of the change?
- Which type or types of tissue receptor are involved in this condition?
- Explain the mechanism by which the organophosphate insecticides induce this state.
- Which clinical drug group do the organophosphate insecticides closely resemble in terms of their action? Why?
- Which drug group can be used as an antidote to oppose the effects of the insecticide? Why?

**CASE STUDY 3**

Mr JJ, aged 68 years, visits the outpatient clinic for a check-up relating to his asthma condition. He has occasional bouts of acute asthma, which is adequately controlled using a salbutamol inhaler. Mr JJ indicates that he has just been diagnosed with open-angle glaucoma, which is being treated with timolol 0.25% eye drops. He inserts one drop in each eye twice daily. The outpatient nurse ascertains that he has used the eye drops for two days.

**Questions**

- To which drug group does salbutamol belong and how does it act to relieve asthma? You may wish to refer to Chapter 27.
- To which drug group does timolol belong, and how does it act to lower intraocular pressure? You may wish to refer to Chapters 27 and 83.
- What is the potential problem for Mr JJ using salbutamol and timolol?

**CASE STUDY 4**

Ms RW is a 50-year-old woman who is suffering from sinus bradycardia (a slow heart rate). Recently, she has had some problems maintaining a normal blood pressure. She is given a medicine that acts on the autonomic innervation of the heart and returns her heart rate to normal.

**Questions**

- State the divisions involved, the transmitters released, the receptors concerned and the effects associated with autonomic nervous system innervation of the heart.
- Name the possible cholinergic and/or adrenergic drug groups that could be used to reverse Ms RW's bradycardia.

**Chapter Review** summarises the essential information in each chapter, providing a quick revision tool.

1106 SECTION XV MEDICINES USED TOPICALLY

### REVIEW QUESTIONS

- 1 What are the major functions of skin?
- 2 Indicate the major characteristics of each of the following skin layers:
  - a dermis
  - b stratum basale
  - c stratum corneum
- 3 Outline the major characteristics of each of the following skin preparations:
  - a lotion
  - b gel
  - c rubefacient
  - d keratolytic
  - e cream
- 4 For each of the following drug groups, indicate the skin condition(s) that they are used to treat:
  - a antimicrobial agents
  - b corticosteroids
  - c immunomodulators
  - d keratolytics
- 5 Outline the pathophysiology of the following two conditions:
  - a acne
  - b psoriasis
- 6 For each of the following agents used in the management of psoriasis, indicate whether it is directed towards reducing the inflammation or the rate of cell proliferation:
  - a the corticosteroids
  - b methotrexate
  - c PUVA therapy
  - d cyclosporin
- 7 Ebony Tinselle is 17 years old and receiving treatment with the retinoid isotretinoin for severe acne. What medicine education would you offer Ebony?
- 8 Mark Mitchell is a 35-year-old man about to commence methotrexate therapy for psoriasis. What baseline examinations are required for this therapy? What advice should Mark receive regarding his therapy?
- 9 Two of the four primary school-aged children in Charlotte Austen's family have head lice infestations. Charlotte buys a shampoo containing piperonyl butoxide and a pyrethrin. Briefly outline the treatment approach to eradicate the infestation.
- 10 Judy Jones, a 35-year-old mother of two young children, is ordered a dithranol preparation to treat her psoriasis. With what medicine education would you provide her for the application of dithranol? What extra care should she take when tending to her children?
- 11 Martha Bortolis, a 15-year-old student, complains of pimples and blackheads on her face and back. As the health professional who examines Martha, you recommend a benzoyl peroxide cream to treat the acne. How would you advise Martha on the use of the cream?
- 12 Jack Brown, aged 55 years, begins a course of treatment with minoxidil liquid for the treatment of androgenic alopecia. What counselling would you offer Mr Brown about using this liquid?

**Review Questions** check that students remember and understand the clinical significance of key chapter content.

**Further Reading** lists appear at the end of each section and provide information for students wishing to pursue a topic in further detail for assessment or interest.

CHAPTER 21 PAEDIATRIC AND GERIATRIC PHARMACOLOGY 207

### FURTHER READING

Buxton R, 2006, 'Pharmacokinetics and pharmacodynamics: the dynamics of drug absorption, distribution and elimination', in Brunton LL, Lazo JS & Parker KL (eds), *Goodman and Gilman's Pharmacological Basis of Therapeutics*, 11th edn, McGraw-Hill, New York, pp. 1–39.

Eshkoli T, Sheiner E, Ben-Zvi Z & Holkberg G, 2011, Drug transport across the placenta, *Current Pharmaceutical Biotechnology*, 12(5): 707–14.

Hughes CM, Rousehead E & Kense N, 2008, 'Improving use of medicines for older people in long-term care: contrasting the policy approach of four countries', *Healthcare Policy*, 3(3): e154–e167.

Jacqz-Aigrain E & Choonara I, eds, 2006, *Paediatric Clinical Pharmacology*, Informa HealthCare, London.

Khojasteh SC, Wong H & Hop CECA, 2011, *Drug Metabolism and Pharmacokinetics Quick Guide*, Springer, New York.

Koch S, Gloth MF, Nay R (eds), 2010, *Medication Management in Older Adults: a Concise Guide for Clinicians*, Springer Science and Business Media, New York.

Le Couteur D, McLachlan A & de Cabo R, 2012, Aging, drugs, and drug metabolism, *Journals of Gerontology, Series A: Biological Sciences & Medical Sciences*, 67(2): 137–39.

McCance K & Huether SE, 2009, *Pathophysiology*, 6th edn, Elsevier Mosby, Sydney (for age-related and disease-related changes in body structure and function).

Sisung TM, Trouman SM, Campbell TJ, Piesler HM, Sung H, Bates SE and Figg WD, 2012, Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy, *Discovery Medicine*, 13(68): 19–34.

The Royal Australian College of General Practitioners, Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists, Pharmaceutical Society of Australia, 2012, *Australian Medicines Handbook*, AMH Pty Ltd, Adelaide.

Weier N, He SM, Li XT, Wang LL & Zhou SF, 2008, 'Placental drug disposition and its clinical implications', *Current Drug Metabolism*, 9, 106–21.

### WEB RESOURCES

Australian Government Department of Health and Ageing [www.health.gov.au](http://www.health.gov.au)

Australian Statistics on Medicines [www.tga.gov.au/hp/medicines-statistics-2010.htm](http://www.tga.gov.au/hp/medicines-statistics-2010.htm)

Clinical Trials (US site) [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

Health Insite [www.healthinsite.gov.au/index.cfm](http://www.healthinsite.gov.au/index.cfm)

Interactive Clinical Pharmacology [www.icp.org.nz](http://www.icp.org.nz)

Medicines Australia (Pharmaceutical Industry Group) [www.medicinesaustralia.com.au](http://www.medicinesaustralia.com.au)

Medsafe [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

NZ Ministry of Health [www.moh.govt.nz/moh.nsf](http://www.moh.govt.nz/moh.nsf)

Pharmacokinetics: An Introduction (US site) [www.4um.com/tutorial/science/pharmak.htm](http://www.4um.com/tutorial/science/pharmak.htm)

Therapeutic Goods Administration (TGA) [www.tga.gov.au/index.htm](http://www.tga.gov.au/index.htm)

Trials Central: online register of US clinical trials [www.trialscentral.org](http://www.trialscentral.org)

CHAPTER 58 ANTIEMETIC AGENTS 745

### WEB RESOURCES

Better Health Channel: Haemorrhoids [www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Haemorrhoids](http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Haemorrhoids)

Centre for Digestive Diseases: Disease Information [www.cdd.com.au](http://www.cdd.com.au)

Crohn's and Colitis Australia [www.acca.net.au](http://www.acca.net.au)

Gastroenterological Society of Australia: Professional Information [www.gesa.org.au](http://www.gesa.org.au)

Health Insite: Digestion and Stomach Disorders [www.healthinsite.gov.au/topics/Digestion\\_and\\_Stomach\\_Disorders](http://www.healthinsite.gov.au/topics/Digestion_and_Stomach_Disorders)

Medline Plus: Constipation (US site) [www.nlm.nih.gov/medlineplus/constipation.html](http://www.nlm.nih.gov/medlineplus/constipation.html)

Medline Plus: Nausea and Vomiting (US site) [www.nlm.nih.gov/medlineplus/nauseaandvomiting.html](http://www.nlm.nih.gov/medlineplus/nauseaandvomiting.html)

Nausea and Vomiting During Pregnancy (Canadian site) [www.sogc.org/health/pregnancy-nausea\\_e.asp](http://www.sogc.org/health/pregnancy-nausea_e.asp)

Primary Care Society for Gastroenterology (UK site) [www.pcsig.org.uk](http://www.pcsig.org.uk)

**Web Resources** lists appear at the end of each section and provide links to relevant websites for further study and online research.

# TEACHING AND LEARNING PACKAGE

The screenshot shows the MyHealthProfessionsKit website interface. At the top, the logo 'MyHealthProfessionsKit®' is on the left, and 'Bullock and Manias Fundamentals of Pharmacology 7th edition' is on the right. Below the logo is a navigation bar with 'HOME', 'STUDY PLAN', 'MULTIMEDIA', and 'INSTRUCTOR' tabs. The main content area has a 'Welcome' header. On the left is a book cover for 'Fundamentals of Pharmacology 7th Edition' by Shane Bullock and Elizabeth Manias, published by Pearson. The cover features a blue and green background with anatomical diagrams and chemical structures. To the right of the cover, the text reads: 'Fundamentals of Pharmacology 7th Edition', 'Shane Bullock and Elizabeth Manias', and 'The materials on this website are to support the text written by Shane Bullock, Monash University, and Elizabeth Manias, University of Melbourne.'

## FOR STUDENTS

MyHealthProfessionsKit is an online study tool that will help you understand, revise and master the concepts in the textbook.

MyHealthProfessionsKit gives you access to these study resources:

- multiple-choice revision questions;
- interactive 'drag and drop' revision activities;
- animations demonstrating the mechanisms of action for various medicines;
- glossary flashcards to test your knowledge of key pharmacology terms;
- realistic drug calculation scenarios to give you practice;
- searchable eBook (if you have purchased the MyLab with eBook option).

## FOR INSTRUCTORS

### Computerised TestBank

Create professional-looking customised printed or online exams in just minutes using Pearson's TestGen software. Build tests from the database of over than 600 true-false and multiple-choice questions, edit questions or add questions of your own.

### PowerPoint Slides

Lecture slides pair key points with images from each chapter to facilitate effective lectures and classroom discussions.

### Solutions Manual

This manual provides the answers to the end-of-chapter exercises in the text. You have the option of making this manual available to your students.

### Digital Media Library

All figures and tables from the textbook are provided in jpeg format.



# FIGURES AND TABLES

<b>FIGURE</b>	<b>1.1</b>	A time line highlighting some major pharmaceutical events	4
	<b>1.2</b>	Medicinal plants commonly found in suburban gardens	6
	<b>2.1</b>	Prescription indicating that brand substitution is permitted	13
	<b>7.1</b>	Appropriate technique for administering eye drops	62
	<b>7.2</b>	Appropriate technique for administering ear drops	62
	<b>7.3</b>	Location of sublingual and buccal sites	63
	<b>7.4</b>	Design of patches used for transdermal administration of medicines	65
	<b>7.5</b>	Nebuliser unit with nebuliser, oxygen tubing and mask	72
	<b>7.6</b>	Use of a metered-dose inhaler	72
	<b>7.7</b>	Use of a spacer in a young child	72
	<b>9.1</b>	Intravenous fluid chart	84
	<b>9.2</b>	The national inpatient medication chart	86
	<b>9.3</b>	Example of a completed medication chart	87
	<b>9.4</b>	Request for cross-matching	88
	<b>9.5</b>	Once-only medicines and health professional-initiated medications chart	89
	<b>9.6</b>	Additive label	89
	<b>9.7</b>	Additive label	89
	<b>9.8</b>	Observation chart	90
	<b>9.9</b>	Diabetic chart	91
	<b>10.1</b>	Sequence of events and checking procedure for medicine administration	94
	<b>13.1</b>	An example of drug nomenclature	129
	<b>13.2</b>	Molecular structures of three tricyclic antidepressants	131
	<b>14.1</b>	Drug absorption between body compartments	134
	<b>14.2</b>	Factors influencing drug absorption	136
	<b>14.3</b>	Protein-bound drug reservoir	137
	<b>14.4</b>	Ion trapping	138
	<b>14.5</b>	Apparent volume of distribution	139
	<b>15.1</b>	Drug metabolism	143
	<b>15.2</b>	Differences in spatial molecular arrangements of glucose and galactose	144
	<b>15.3</b>	The enterohepatic cycle	145
	<b>15.4</b>	Hepatic first-pass effects	146
	<b>15.5</b>	Drug excretion	147
	<b>15.6</b>	The development of a steady-state concentration	148
	<b>15.7</b>	The effect of a loading dose on plasma concentration	149
	<b>15.8</b>	Kinetics of drug metabolism	149

<b>FIGURE</b>	<b>16.1</b>	Common sites of drug interactions	156
	<b>17.1</b>	Competitive inhibition of enzyme–substrate reactions	162
	<b>17.2</b>	Structures of 4-aminobenzoic acid and a sulfonamide, sulfamethoxazole	163
	<b>17.3</b>	Non-competitive inhibition of enzyme-substrate reactions	164
	<b>17.4</b>	Receptor sites of drug action	165
	<b>17.5</b>	Agonist and antagonist action	166
	<b>17.6</b>	Relative drug potency and efficacy	167
	<b>18.1</b>	Time-line and costs for development and evaluation of new drugs	172
	<b>18.2</b>	Graph of blood drug concentration showing the margin of safety	174
	<b>18.3</b>	Type I hypersensitivity reaction	175
	<b>18.4</b>	Type II hypersensitivity reaction	176
	<b>18.5</b>	Type III hypersensitivity reaction	176
	<b>18.6</b>	Type IV hypersensitivity reaction	177
	<b>19.1</b>	Normally distributed drug responsiveness at the population level	183
	<b>19.2</b>	Bimodal drug responsiveness at the population level	183
	<b>19.3</b>	Tailoring drug treatment to the individual	184
	<b>19.4</b>	Potential clinical consequences of genetic polymorphism	185
	<b>21.1</b>	Administering medicine to a small child using a dropper	199
	<b>21.2</b>	Example of a dose-administration aid	201
	<b>21.3</b>	Sample morning and afternoon medicine clocks for use by an older person	202
	<b>22.1</b>	Principles associated with the management of poisoning	211
	<b>22.2</b>	Examples of terrestrial animals that pose a risk to humans	215
	<b>23.1</b>	Principles associated with the management of an overdose	220
	<b>23.2</b>	Gastric tubes that can be used for the rapid evacuation of gastric contents	221
	<b>23.3</b>	Patient positioning during gastric lavage	221
	<b>23.4</b>	Paracetamol treatment nomograph for Australia and New Zealand	222
	<b>25.1</b>	Pharmacological effects of anabolic steroids	242
	<b>26.1</b>	Divisions of the nervous system	251
	<b>26.2</b>	Schematic representation of a typical autonomic nervous system pathway	253
	<b>26.3A</b>	The characteristics of a sympathetic nerve pathway	254
	<b>26.3B</b>	The characteristics of a parasympathetic nerve pathway	254
	<b>27.1</b>	Adrenergic nerve action	260
	<b>27.2</b>	Adrenergic agonist effects	261
	<b>27.3</b>	Flowchart showing the effects of $\alpha_1$ agonists	263
	<b>27.4</b>	The effects of $\alpha_1$ agonists	264
	<b>27.5</b>	Flowchart showing the effects of $\beta_1$ agonists	265
	<b>27.6</b>	The effects of $\beta_1$ agonists	266
	<b>27.7</b>	Flowchart showing the effects of $\beta_2$ agonists	267
	<b>27.8</b>	The effects of $\beta_2$ agonists	268

<b>FIGURE</b>	<b>27.9</b>	Intracellular events triggered by the action of a first messenger	269
	<b>27.10</b>	Second messengers involved in adrenergic function	270
	<b>27.11</b>	Direct- and indirect-acting sympathomimetics	271
	<b>27.12</b>	Adrenergic antagonist effects	273
	<b>27.13</b>	Flowchart showing the effects of $\alpha$ antagonists	274
	<b>27.14</b>	The effects of $\alpha$ antagonists	275
	<b>27.15</b>	Flowchart showing the effects of $\beta$ antagonists	276
	<b>27.16</b>	The effects of $\beta$ antagonists	277
	<b>27.17</b>	Flowchart showing the effects of dopamine agonists	278
	<b>28.1</b>	Cholinergic nerve stimulation	287
	<b>28.2</b>	Flowchart showing the effects of nicotinic receptor agonists	289
	<b>28.3</b>	The effects of nicotinic receptor agonists	290
	<b>28.4A</b>	Flowchart showing the effects of muscarinic receptor ( $M_1$ and $M_2$ ) agonists	291
	<b>28.4B</b>	Flowchart showing the effects of muscarinic receptor ( $M_3$ ) agonists	292
	<b>28.5</b>	The effects of muscarinic receptor agonists	293
	<b>28.6</b>	Cholinergic agonist effects	294
	<b>28.7</b>	Cholinergic antagonist effects	295
	<b>28.8</b>	Flowchart showing the effects of nicotinic receptor antagonists	296
	<b>28.9</b>	The effects of nicotinic receptor antagonists	297
	<b>28.10A</b>	Flowchart showing the effects of muscarinic ( $M_1$ and $M_2$ ) antagonists	299
	<b>28.10B</b>	Flowchart showing the effects of muscarinic ( $M_3$ ) antagonists	300
	<b>28.11</b>	The effects of muscarinic antagonists	301
	<b>30.1</b>	The action of histamine and antihistamines at $H_1$ receptors	322
	<b>30.2</b>	The effects of the classic antihistamines	323
	<b>31.1</b>	Pathway for prostaglandin synthesis and sites of drug action	330
	<b>32.1</b>	The physiological effects of nitric oxide	339
	<b>32.2</b>	The physiological effects of the endothelins	340
	<b>33.1</b>	Principal parts of the human brain	348
	<b>34.1</b>	Flowchart showing the effects of first-generation (typical) antipsychotics	357
	<b>34.2</b>	Important adverse effects associated with the second-generation (atypical) antipsychotics	359
	<b>35.1</b>	Mechanism of action of the benzodiazepines on GABA receptors	369
	<b>35.2</b>	The effects of the benzodiazepines	370
	<b>35.3</b>	Mechanism of action of the barbiturates on GABA receptors	373
	<b>36.1</b>	Monoamine nerve function	382
	<b>36.2</b>	Proposed synaptic sites of action of the antidepressant agents	383
	<b>36.3</b>	The mechanism of action and adverse effects of the antidepressant drugs	384
	<b>37.1</b>	Diagrammatic representation of (A) normal and (B) abnormal nigrostriatal pathway functioning	400
	<b>37.2</b>	The effects of levodopa	402

<b>FIGURE</b>	<b>37.3</b>	Anti-Parkinsonian agents and their common adverse effects	406
	<b>37.4</b>	The effects of the acetylcholinesterase inhibitors	407
	<b>38.1</b>	Sites of action of antiseizure agents	421
	<b>38.2</b>	Sites of action of muscle relaxants	429
	<b>39.1</b>	The effects of methylphenidate and dexamphetamine	439
	<b>40.1</b>	The pain transmission pathway	451
	<b>40.2</b>	Self-reporting measures for the intensity of pain	452
	<b>40.3</b>	Analgesic chart for documenting pain assessment and management	453
	<b>40.4</b>	World Health Organization ladder of analgesia	453
	<b>40.5</b>	The effects of narcotics	455
	<b>40.6</b>	Flowchart showing the effects of narcotic analgesics	456
	<b>41.1</b>	Biosynthesis of prostaglandins and related mediators with the site of action of the NSAIDs	468
	<b>41.2</b>	Flowchart showing the effects of NSAIDs	470
	<b>41.3</b>	The effects of NSAIDs	471
	<b>42.1</b>	Pathophysiological changes in cerebral blood flow underlying migraine headaches	489
	<b>43.1</b>	The actions of general anaesthetics on membrane ion channels	500
	<b>44.1</b>	The nerve action potential	509
	<b>44.2</b>	States of activation in voltage-gated membrane channels	509
	<b>44.3</b>	The physiology of nerve transmission	510
	<b>45.1</b>	Cholesterol transport	524
	<b>45.2</b>	The effects of the statins	528
	<b>46.1</b>	Blood pressure control mechanisms	536
	<b>46.2</b>	The sites of action of anti-hypertensive agents	539
	<b>46.3</b>	Flowchart showing the effects of the angiotensin receptor antagonists	541
	<b>46.4</b>	Flowchart showing the effects of the $\alpha_1$ antagonists	543
	<b>47.1</b>	Pathophysiology and rationale of pharmacological therapy of an angina attack	557
	<b>47.2</b>	Flowchart showing the effects of the organic nitrates	559
	<b>47.3</b>	The effects of organic nitrates	560
	<b>47.4</b>	Flowchart showing the effects of calcium channel antagonists	562
	<b>47.5</b>	The effects of calcium channel blockers	563
	<b>47.6</b>	Sites of action of drugs that produce smooth muscle relaxation	566
	<b>48.1</b>	Normal coagulation and sites of anticoagulant action	574
	<b>48.2</b>	Platelet adhesiveness and medicines that impair this process	580
	<b>49.1</b>	Nephron physiology and the sites of action of renal medicines	596
	<b>49.2</b>	The effects of the thiazides and related diuretics	598
	<b>50.1</b>	Flowchart showing the pathophysiology of heart failure	609
	<b>50.2</b>	Flowchart showing the effects of the angiotensin-converting enzyme inhibitors	611
	<b>50.3</b>	The effects of angiotensin-converting enzyme inhibitors	612
	<b>50.4</b>	Flowchart showing the effects of carvedilol	614



<b>FIGURE</b>	<b>50.5</b>	The neurophysiological actions of cardiac glycosides	616
	<b>50.6</b>	Flowchart showing the effects of drugs on the pathophysiological process of heart failure	620
	<b>51.1</b>	Voltage-gated membrane channels with one gate	627
	<b>51.2</b>	Voltage-gated membrane channels with two gates	628
	<b>51.3</b>	The generalised myocardial action potential	628
	<b>52.1</b>	Distribution of body compartments	637
	<b>52.2</b>	Movement of fluid across the capillary	638
	<b>52.3</b>	Schematic representation of changes in fluid pressure that lead to oedema	639
	<b>52.4</b>	Effects of adding different fluids to the intravascular compartment	641
	<b>52.5</b>	Effects of crystalloid, colloid and a combination of both fluids in the treatment of hypovolaemic shock	643
	<b>54.1</b>	The pathophysiology of extrinsic asthma	661
	<b>54.2</b>	The phases of an asthma attack	661
	<b>54.3</b>	Flowchart showing the effects of $\beta_2$ agonists	663
	<b>54.4</b>	Flowchart showing the effects of antimuscarinic medicines	665
	<b>54.5</b>	Flowchart showing the effects of methylxanthine bronchodilators	667
	<b>55.1</b>	Flowchart showing the effects of $\alpha_1$ agonists	685
	<b>56.1</b>	Gastric acid production and the sites of action of anti-ulcerant medicines	703
	<b>56.2</b>	The effects of the histamine $H_2$ -receptor antagonists	704
	<b>56.3</b>	The effects of the proton pump inhibitors	705
	<b>57.1</b>	Mechanisms of action of laxatives	715
	<b>58.1</b>	Pathophysiology of vomiting and the sites and mechanisms of action of antiemetic agents	735
	<b>58.2</b>	The effects of the phenothiazine antiemetics and related agents	737
	<b>59.1</b>	The effects of pituitary hormones and sites of action of medicines affecting pituitary function	751
	<b>61.1</b>	Correct position for inserting an insulin injection	773
	<b>61.2</b>	Sites of amino acid substitution in the insulin molecule required to make the short-acting insulin analogues	775
	<b>61.3</b>	A chronic complication of diabetes mellitus	777
	<b>61.4</b>	Flowchart showing the effects of the sulfonylureas	779
	<b>61.5</b>	Flowchart showing the effects of the biguanides	780
	<b>61.6</b>	Flowchart showing the effects of the thiazolidinediones	782
	<b>61.7</b>	Sites of action of the hypoglycaemic agents	785
	<b>62.1</b>	The effects of glucocorticoids	793
	<b>62.2</b>	The mechanism of action of metyrapone	795
	<b>63.1</b>	Sites of action of sex hormone antagonists	813
	<b>64.1</b>	Cells involved in bone metabolism	823
	<b>64.2</b>	Calcium homeostasis	824
	<b>64.3</b>	Vitamin D metabolism	825

<b>FIGURE</b>	<b>65.1</b>	Mechanism of action of uricosuric agents	836
	<b>65.2</b>	Purine metabolism	837
	<b>66.1</b>	The physiological regulation of food intake	844
	<b>66.2</b>	The effects of the stimulant anorectics	846
	<b>67.1</b>	The organs and body systems on which each vitamin has its major effect	857
	<b>67.2</b>	Structural formulae of nicotine and nicotinic acid	860
	<b>67.3</b>	The stereoisomers of serine	870
	<b>68.1</b>	Percutaneous endoscopic gastrostomy (PEG) tube placement	877
	<b>68.2</b>	Total parenteral nutrition through a central venous catheter in the right subclavian vein	881
	<b>69.1</b>	The spiky leaves of the aloe vera plant	887
	<b>69.2</b>	The chamomile daisy, <i>matricaria recutita</i>	888
	<b>69.3</b>	Cranberry	888
	<b>69.4</b>	The <i>echinacea purpurea</i> maxima flower	889
	<b>69.5</b>	Evening primrose flower	890
	<b>69.6</b>	The feverfew daisy	890
	<b>69.7</b>	A basket of garlic bulbs	891
	<b>69.8</b>	Ginger	892
	<b>69.9</b>	Ginkgo	892
	<b>69.10</b>	Ginseng	893
	<b>69.11</b>	Flower of the red clover	894
	<b>69.12</b>	St John's wort ( <i>hypericum</i> )	895
	<b>69.13</b>	Saw palmetto	895
	<b>69.14</b>	Valerian	896
	<b>70.1</b>	Mechanisms of action of antimicrobial agents	910
	<b>70.2</b>	Activity of time-dependent antimicrobial agents	914
	<b>70.3</b>	Activity of concentration-dependent antimicrobial agents	914
	<b>71.1</b>	The sites of action of the sulfonamides and trimethoprim in DNA/RNA synthesis	918
	<b>72.1</b>	Mechanism of action of antibacterial medicines that inhibit cell wall synthesis	924
	<b>72.2</b>	Mechanism of action of antibacterial medicines that inhibit protein synthesis	928
	<b>72.3</b>	Mechanism of action of the synthetic antibacterial medicines affecting metabolism	933
	<b>72.4</b>	Mechanism of action of antibacterial medicines affecting plasma membrane permeability	933
	<b>73.1</b>	Actions of the antituberculous agents	949
	<b>74.1</b>	Basic structure of a quaternary compound	963
	<b>74.2</b>	The hexadecanyl group	963
	<b>75.1</b>	Sites of action of the antiprotozoal agents	971
	<b>75.2</b>	Sites of action of the anthelmintic medicines	974

FIGURE	76.1	Life cycle of <i>Plasmodium</i>	982
	77.1	The process of viral infection in a human host cell	992
	77.2	Common sites of action of antiviral agents	993
	78.1	Cellular sites of action of antifungal agents	1014
	79.1	The proliferation of immune cells in an immune response	1027
	80.1	The cell cycle	1051
	80.2	The folic acid pathway and sites of action of folic acid analogues	1056
	81.1	Gene therapy techniques	1081
	82.1	The structure of skin	1091
	83.1	The parts of the eye	1112
	83.2	The pathophysiology of glaucoma	1118

<b>TABLE</b>	<b>2.1</b>	Common features of polypharmacy	14
	<b>2.2</b>	Consequences of polypharmacy	14
	<b>3.1</b>	Control over medicine use in Australian state and territory legislation	22
	<b>3.2</b>	Standard for the uniform scheduling of drugs and poisons in Australia	23
	<b>3.3</b>	Grouping of medicines in New Zealand	24
	<b>3.4</b>	Scheduling of controlled substances in New Zealand	24
	<b>3.5</b>	Information required on a ward register for the administration of drugs of dependence	26
	<b>3.6</b>	Steps required for telephone orders of prescription medicines	27
	<b>3.7</b>	Steps required for standing orders of prescription medicines	27
	<b>4.1</b>	Ethical principles and their meanings	31
	<b>4.2</b>	Requirements for informed and valid consent	31
	<b>5.1</b>	Factors affecting a person's adherence to medicine regimens	40
	<b>5.2</b>	Client teaching through the clinical decision-making process	41
	<b>7.1</b>	Administering medicines by the oral route	59
	<b>7.2</b>	Administering medicines by the nasogastric route	60
	<b>7.3</b>	Administering medicines by the optic route	61
	<b>7.4</b>	Administering medicines by the aural route	61
	<b>7.5</b>	Administering medicines topically (on the skin)	62
	<b>7.6</b>	Administering medicines by the sublingual/buccal route	63
	<b>7.7</b>	Administering medicines by the nasal route: drops	64
	<b>7.8</b>	Administering medicines by the nasal route: sprays	64
	<b>7.9</b>	Examples of transdermal products	65
	<b>7.10</b>	Administering medicines by the transdermal route	65
	<b>7.11</b>	Administering medicines by the rectal route: suppositories	66
	<b>7.12</b>	Administering medicines by the rectal route: enemas	67
	<b>7.13</b>	Administering medicines by the vaginal route	68
	<b>7.14</b>	Administering medicines by the subcutaneous route	69
	<b>7.15</b>	Administering medicines by the intramuscular route	70
	<b>7.16</b>	Administering medicines by the intravenous route	71
	<b>7.17</b>	Administering medicines by the respiratory route: inhalers	73
	<b>7.18</b>	Administering medicines by the respiratory route: nebulisers	73
	<b>7.19</b>	Shelf life of preparations after opening	74
	<b>11.1</b>	Respiratory depression	98
	<b>11.2</b>	Anaphylactic shock	99
	<b>11.3</b>	Dizziness	100
	<b>11.4</b>	Constipation	101
	<b>11.5</b>	Hypertension	101
	<b>11.6</b>	Hypotension	102
	<b>11.7</b>	Oral candidiasis (oral thrush)	103
	<b>11.8</b>	Rash	103
	<b>11.9</b>	Dry mouth	104
	<b>11.10</b>	Nausea	105



<b>TABLE</b>	<b>11.11</b>	Drowsiness/sedation	105
	<b>11.12</b>	Fever	106
	<b>11.13</b>	Photophobia	107
	<b>11.14</b>	Stomatitis	107
	<b>11.15</b>	Diarrhoea	108
	<b>11.16</b>	Anogenital candidiasis	109
	<b>11.17</b>	Vomiting	109
	<b>11.18</b>	Blistering	110
	<b>11.19</b>	Photosensitivity	110
	<b>11.20</b>	Postural hypotension	111
	<b>12.1</b>	Determination of relative risk	115
	<b>12.2</b>	Determination of the population absolute risk	116
	<b>12.3</b>	Determination of relative risk reduction and absolute risk reduction	116
	<b>12.4</b>	Effect of increasing the incidence of events	117
	<b>12.5</b>	Effect of increased duration on number needed to treat	118
	<b>13.1</b>	Examples of differing forms of individual generic drugs used in clinical practice	128
	<b>13.2</b>	Suffixes used to identify common drug groups	131
	<b>16.1</b>	Interactions after absorption	154
	<b>16.2</b>	Selected drug interactions associated with cytochrome P450	156
	<b>18.1</b>	Categorisation of medicines in pregnancy	179
	<b>21.1</b>	Reasons for non-adherence with treatment in older people	200
	<b>21.2</b>	Improving adherence with drug treatments	201
	<b>21.3</b>	Preparations that are not suitable for crushing	203
	<b>21.4</b>	Medicines causing severe adverse drug reactions in the older person	203
	<b>22.1</b>	Chelating agents	213
	<b>22.2</b>	Antivenoms and their sources	216
	<b>25.1</b>	World Anti-Doping Agency (WADA) list of banned substances	240
	<b>26.1</b>	Effects of the parasympathetic and sympathetic divisions on various organs	252
	<b>26.2</b>	Anatomical and physiological differences between the parasympathetic and sympathetic divisions	255
	<b>26.3</b>	Examples of neuromodulators of the autonomic nervous system	256
	<b>27.1</b>	Examples of autonomic second messenger systems	269
	<b>28.1</b>	Pharmacokinetic profiles of some non-depolarising neuromuscular blocking agents	298
	<b>29.1</b>	The classification of chemical mediators	315
	<b>29.2</b>	Examples of peptide and protein mediators	316
	<b>30.1</b>	Histamine receptor subtype locations and effects	319
	<b>31.1</b>	General actions of prostaglandins	331
	<b>31.2</b>	Some actions of serotonin at different receptor sites	333
	<b>33.1</b>	Brain regions and chemical transmitters	350
	<b>34.1</b>	Classification of dopamine receptor subtypes	353

<b>TABLE</b>	<b>34.2</b>	Tendency of antipsychotics to cause adverse effects	355
	<b>35.1</b>	Types of common anxiety disorders	368
	<b>35.2</b>	Half-lives and therapeutic uses of some benzodiazepines	371
	<b>36.1</b>	Types of depression	381
	<b>36.2</b>	Tyramine-containing foods	387
	<b>37.1</b>	Treatment regimen for combined therapy in Parkinson's disease	406
	<b>37.2</b>	Medicines used in the symptomatic treatment of multiple sclerosis	410
	<b>38.1</b>	Medicines that may produce seizure-like symptoms	419
	<b>38.2</b>	Common seizure types and their major characteristics	420
	<b>38.3</b>	Common medicines used to treat seizure types	422
	<b>40.1</b>	Pain history	452
	<b>40.2</b>	Endogenous opioid receptors	454
	<b>40.3</b>	Equianalgesic agent table	457
	<b>41.1</b>	Pharmacokinetic characteristics of NSAIDs and related medicines	472
	<b>43.1</b>	The major contraindications of inhalation anaesthetics	501
	<b>44.1</b>	Local anaesthetics comparative information	513
	<b>45.1</b>	Desirable population blood lipid levels	524
	<b>46.1</b>	Coexisting conditions and the antihypertensive agents	548
	<b>48.1</b>	Some substances that promote or inhibit haemostasis	575
	<b>48.2</b>	Some medicines that increase warfarin activity	579
	<b>48.3</b>	Some medicines that decrease warfarin activity	579
	<b>50.1</b>	New York Heart Association's (NYHA) classification of heart failure	608
	<b>51.1</b>	Classes of antidysrhythmic agents and their applications	630
	<b>52.1</b>	Distribution of body fluids and fat at different ages	637
	<b>52.2</b>	Definitions of pressures existing at the capillary level	638
	<b>52.3</b>	Clinical indications for fluid therapy	641
	<b>52.4</b>	Blood products	644
	<b>52.5</b>	Colloid solutions	645
	<b>52.6</b>	Examples of crystalloid solutions	646
	<b>52.7</b>	Causes of hypokalaemia	647
	<b>52.8</b>	Foods rich in potassium	647
	<b>52.9</b>	Causes of hyperkalaemia	648
	<b>54.1</b>	Signs of poor asthma control	671
	<b>54.2</b>	How to help a person with asthma to achieve medicine adherence	671
	<b>54.3</b>	Management of asthma according to severity of symptoms	671
	<b>54.4</b>	First aid management of an asthma attack	672
	<b>54.5</b>	Management of COPD according to severity of symptoms	672
	<b>56.1</b>	Actions of prostaglandins on some digestive functions	705
	<b>57.1</b>	Characteristics of laxative categories	716
	<b>57.2</b>	Some common bulk-forming laxatives	719
	<b>59.1</b>	Pituitary hormones and their effects	750
	<b>60.1</b>	Major effects of thyroid hormone ( $T_4$ and $T_3$ ) in the body	763
	<b>61.1</b>	Insulin preparations and their pharmacokinetics	776

<b>TABLE</b>	<b>61.2</b>	Medicines that may raise or lower blood glucose concentration	776
	<b>62.1</b>	Adrenocortical hormones and their effects	792
	<b>62.2</b>	Some corticosteroid potencies compared with hydrocortisone	794
	<b>63.1</b>	Summary of hormonal effects of oestrogens, progesterone and testosterone	802
	<b>63.2</b>	Progestogen-only contraceptive preparations	806
	<b>63.3</b>	Oral contraceptive preparations	808
	<b>63.4</b>	Advice on a missed dose of an oestrogen–progestogen combined oral contraceptive pill	810
	<b>63.5</b>	Advice on a missed dose of a progestogen-only contraceptive pill	810
	<b>63.6</b>	Process for changing contraceptive pills	810
	<b>66.1</b>	Suggestions for safe and effective weight loss	845
	<b>67.1</b>	Amino acids used in therapy	871
	<b>68.1</b>	Types of enteral feed	878
	<b>68.2</b>	Management of enteral feed intolerance	879
	<b>68.3</b>	Complications of enteral nutrition	880
	<b>68.4</b>	Indications for parenteral nutrition	881
	<b>68.5</b>	Complications of parenteral nutrition	882
	<b>70.1</b>	Surgical and nonsurgical conditions requiring antimicrobial prophylactic therapy	915
	<b>72.1</b>	Extended-spectrum $\beta$ -lactamases	925
	<b>74.1</b>	Examples of cationic detergents	963
	<b>78.1</b>	Common forms of tinea and the affected body regions	1013
	<b>79.1</b>	A selection of important cytokines	1028
	<b>79.2</b>	Antisera preparations and their sources	1031
	<b>79.3</b>	Vaccines	1031
	<b>79.4</b>	Mixed vaccines	1033
	<b>80.1</b>	Characteristics of protein kinase inhibitors	1066
	<b>80.2</b>	Some common cytotoxic drug combinations	1071
	<b>81.1</b>	Advantages and disadvantages of the viral vectors	1082
	<b>83.1</b>	Autonomic nervous innervation of the eye	1113

## SECTION

# I

# PHARMACOLOGY WITHIN THE SOCIAL CONTEXT

*O, (abundant) is the powerful grace that lies  
In herbs, plants, stones ...*

WILLIAM SHAKESPEARE—*ROMEO AND JULIET*

The quote from Shakespeare's *Romeo and Juliet* alludes to two important points explored in this section. The first is that medicines can be obtained from a variety of sources within our environment. The other is that these substances produce a powerful effect on the body. The nature of the effect of medicines, both desired and unwanted, is the main theme of this book. Historical records show that medicine use has long been a part of human culture. A brief outline of the history of medicine use and the sources from which medicines are obtained is provided in Chapter 1.

In Chapter 2, we move to the present with a discussion of the sociocultural aspects of pharmacology. Our society is coming to grips with a number of issues related to medicine use, and health professionals must be aware of these issues and implement effective strategies to deal with them. Some of the issues raised in Chapter 2 include the following:

- the use of generic substances versus proprietary medicines;
- medicine advertising;
- perspectives of medicine use in the older person;
- cultural differences;
- the use of over-the-counter (OTC) preparations.

The effect of these issues on health professionals, such as nurses, doctors and pharmacists, is also considered.



# A HISTORICAL PERSPECTIVE

## LEARNING OBJECTIVES

After completing this chapter, you should be able to:

- 1 Define the term pharmacology.
- 2 Identify the roles of medicines in human society.
- 3 Identify the three ages of pharmacology.
- 4 Briefly describe the major characteristics of each of the three ages and their implications for society.

## KEY TERMS

*Biotechnology*  
*Genetic engineering*  
*Natural products*  
*Pharmacology*  
*Recombinant DNA technology*

**Pharmacology** is a branch of medical science that deals with the properties and characteristics of chemical agents used for medicinal or other purposes. The actions and effects of these chemical agents on physiological systems are of particular interest. The physiological systems in which these effects are observed may be organs or tissues isolated from the body and artificially maintained—*in vitro* situations—or within living whole organisms—*in vivo* situations. In an etymological sense, the word 'pharmacology' is derived from two Greek words: *pharmakos*, which means medicine or drug, and *logos*, which means study.



## SUBSTANCE USE AND SOCIETY

The use of chemical substances for medicinal and social purposes mirrors the course of human history itself. In fact, it probably even predates human history, as evidence of medicine use seems apparent among other animals (particularly chimpanzees, which have recently been shown to consume foods for their antibacterial, antifungal or antiworming properties). The methods used to identify useful pharmacological agents involve trial and error as well as careful observation. Indeed, many valuable therapeutic agents were discovered serendipitously during scientific investigations carried out for other purposes. A famous example of this is the discovery of penicillin by Sir Alexander Fleming.

From the most primitive human communities to the most civilised, there exists a culture of using chemical agents for recreational, religious and medicinal purposes. The first recorded systematic register of medicines dates back to the ancient Greek and Egyptian civilisations. In all societies, it is apparent that the individuals who make and administer these agents possess power and influence over their fellows.

## THE AGES OF PHARMACOLOGY

The history of pharmacology is represented by the time line in Figure 1.1. It can be subdivided into three eras according to the characteristics of drug development: the first, in which the use of natural substances dominated; the next, in which products of laboratory chemistry emerged and became pre-eminent; and now, in the early 21st century, when biotechnological products are the focus of attention. While there is some overlap between the three eras, each era tended to dominate at certain time periods.

### The age of natural substances

Probably the earliest known natural substance used because of its profound effects on the human body is alcohol (ethanol). In fact, the process of fermentation is illustrated on pottery from Mesopotamia made around 4200 BCE. While the Mesopotamians would have been aware of the physiological effects of fermented beverages, it is a matter for conjecture whether or not alcohol was ascribed any medicinal properties. We had to wait a couple of millennia before its medicinal uses were documented. Alcohol has been used as a skin antiseptic, rubefacient, an appetite stimulant, a gastric acid stimulant, an analgesic, an anaesthetic and a tocolytic agent. One famous literary example of alcohol's medicinal use is in the Bible in a letter from St Paul to Timothy: '... use a little wine for thy stomach's sake and thine often infirmities'. Today, while the

social use of alcohol dominates any therapeutic applications that might remain, there is some evidence that St Paul's words contain an element of truth (see Chapter 24).

The period in which therapeutic agents were derived from plants is by far the longest: the first recorded use dates back to around 2700 BCE. Every culture throughout history has used plant derivatives—the leaves, fruit, bark, roots, flowers and sap—as a means to heal. Agents such as **atropine**, **ergotamine**, **curare**, **morphine**, **reserpine**, **cocaine** and **marijuana** were extracted from these sources. Indeed, the origins and uses of just a few of these substances broaden the view of pharmacology and remind us that there is more to this area of study than simply popping pills into sick people's mouths.

### ATROPINE: LEGENDS AND LADIES


Atropine is derived from the fruits of various plants of the potato family, particularly the deadly nightshade, *Atropa belladonna*. As is obvious from the common name, the fruits of this plant have long been known to be poisonous. Throughout history, deadly nightshade has been used for nefarious purposes as an effective method of poisoning. Indeed, the scientific name for deadly nightshade does reflect atropine's action. Atropos was one of the three Fates from Greek mythology. She, along with the other two Fates, decided individual destiny. It was her role to dispatch mortals by cutting the threads of life with a pair of shears. Belladonna means 'beautiful lady', and in the early part of the second millennium it was known that extracts from this plant would cause dilation of the pupils, an attribute that was considered desirable in women. This action, although for a non-cosmetic/medical purpose, is still one of the uses of atropine and its derivatives today.

### ERGOTS: HEADACHES, HALLUCINATIONS AND HYSTERIA

Ergotamine and its cousin **ergometrine** are derived from the fungus *Claviceps purpurea*, an important pathogen of the cereal, rye. These two medicines are used respectively to treat migraine and to induce uterine contractions in obstetrics, but in overdose can cause seizures and hallucinations (not surprisingly, as lysergic acid diethylamide, LSD, is a derivative of ergotamine). It has been suggested that many witches in the Middle Ages, and even up to the Salem witchcraft trials in America in the 17th century, could have been tried and burnt at the stake for having been intoxicated after ingesting infected cereals. How many migraine sufferers realise that an overdose of Cafegot (a brand name for an ergotamine preparation) could have had them burnt at the stake in previous eras?

**Figure 1.1** A time line highlighting some major pharmaceutical events

A historical time line showing use of major pharmaceutical substances. The time line is divided into three distinct periods: the age of natural substances; the age of synthetic substances; and the age of biotechnology.



### TUBOCURARINE: MACUSIS AND MUSCLES

**Tubocurarine** has been used in surgery to paralyse skeletal muscle, a procedure that makes the surgeon's task easier. (Nowadays, newer medicines have replaced it.) This medicine is derived from plants belonging to the genus *Strychnos* (some of which also provide strychnine). An impure preparation of the medicine is called curare, and has been used as an arrow poison by the Macusi Indians of Guyana. The interesting fact about this medicine is that

the Macusi, unwittingly, were making use of an important pharmacological property—the nature of medicine absorption. The majority of medicines are given by mouth—but some, if given by this route, are not absorbed. Tubocurarine is one of these. The Indians observed that death would soon come to the shot animal as curare was absorbed into the blood from the arrow wound. However, no harm came to the tribe as they consumed the meat of the animal that had been contaminated with curare.

## OPIUM AND COCA: ASSYRIA, ANALGESIA, THE ANDES AND ANAESTHESIA

Morphine comes from opium, which is the dried exudate of the opium poppy, *Papaver somniferum* (meaning the sleep-bearing poppy). The word morphine itself is derived from the Greek god of dreams, Morpheus. Opium was mentioned in one of the earliest and most influential pharmacology texts, that of Dioscorides, which was published in the first century AD. It is probable that opium was grown in Assyria, Greece and Mesopotamia long before this time. Many people think that opium came originally from China, but it probably did not reach there until at least the 6th century AD.

Cocaine is obtained from the leaves of *Erythroxylum coca*, a shrub that grows wild in the Andes of Peru and Bolivia. It has been used for centuries as a stimulant by the Peruvian Indians of these areas. Its principal action is on the central nervous system but it has some peripheral effects; namely, that it reduces the desire for food and drink because of its local anaesthetic action. This action, much more than its stimulant properties, is the reason for its legitimate therapeutic value today. Today, cocaine is used as a local anaesthetic only occasionally, principally in nasal surgery. Like the Macusi Indians who used curare, the Peruvian Indians who used cocaine crudely applied some pharmacology. The leaves of this plant were mixed with lime prior to chewing. This prolonged the effect of the medicine by altering its rate of excretion from the body, and showed that medicine preparation has an important influence on therapeutic effect in the body. (Medicine preparations are discussed in detail in Chapter 7.)

## RESERPINE: BRAIN IMBALANCE AND BLOOD PRESSURE

Reserpine has an unusual place in the annals of historical pharmacology because its original use in treating mental illness is quite different from its modern use, which is to treat hypertension (although it has now been superseded by other, safer antihypertensive agents). Reserpine comes from the powdered root of *Rauwolfia serpentina*, and was used in India to treat the mentally disturbed. One of the undesirable effects of reserpine is that it can cause depressive illness. This adverse drug reaction helped to establish the theory that depression is not always due to reactions to life events but may well be related to changes in brain biochemistry (i.e. that an imbalance in the level of brain neurotransmitters may underlie the behaviour).

## MARIJUANA: MALINGERER OR MEDICINE?

Marijuana is, in most countries, a substance of abuse; as (until recently) its effects have not been widely considered to be of clinical value. This substance comes from the plant

*Cannabis sativa*, and has been used intermittently since about 2700 BC as a sedative or analgesic. After World War II particularly, it became a common recreational drug, and was outlawed by the World Health Organization as a drug of abuse with no therapeutic use. This may be inaccurate as the main active substance of marijuana,  $\delta$ -9-tetrahydrocannabinol (THC), appears to have more potent antiemetic applications than most other antiemetics. Two related compounds, dronabinol and nabilone, have been approved in some countries for the treatment of the nausea and vomiting associated with the use of anticancer agents. Substances containing (or derived from) THC are called cannabinoids. There are clinical applications for the cannabinoids. An example is as appetite stimulants for people living with HIV/AIDS who experience significant weight loss.

## ANTIBIOTICS: MEDICINAL MOULDS

In the early part of the 20th century, we realised that there were other natural sources of therapeutic substances. Certain fungi and bacteria produce secretions that protect them from, or kill, other microbes. These secretions are known as antibiotics, and are among the most effective means available to combat the many infectious diseases that have plagued humankind (see Section XIV). During the 1930s and 1940s penicillin was isolated and purified, and it became the precursor of other antibiotics, such as **streptomycin** for the treatment of tuberculosis. Interestingly, it was known in ancient times that the application of mouldy bread (presumably contaminated by fungus of the genus *Penicillium*) could help cure wound infections.

## SOURCES OF NATURAL SUBSTANCES

Natural substances with the potential to heal are all around us. You probably have some common clinical agents growing in your gardens at home (see Figure 1.2)—a heart medicine from the purple foxglove (see Chapter 50), atropine from the deadly nightshade (see Chapter 28) and anticancer agents from the common periwinkle plant (see Chapter 80). Indeed, that we are surrounded by natural substances with medicinal properties is the reason for the use of herbal and alternative medicines. However, for many of these natural medicines, evidence of a therapeutic benefit, by the same methods used to authenticate conventional medicines, is less than convincing.

There are many habitats and human cultures that remain relatively unexplored sources of natural medicines. The number of potential medicines that remain undiscovered